Latest Videos

Latest News

Merck Gains Late-Stage Eye Disease Drug Candidate with EyeBio Acquisition

Merck Gains Late-Stage Eye Disease Drug Candidate with EyeBio Acquisition

July 18th 2024

Merck gains a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration through its acquisition of EyeBio.

Lantheus Acquires Meilleur Technologies, PET Imaging Agent

Lantheus Acquires Meilleur Technologies, PET Imaging Agent

July 15th 2024

The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.

Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition

Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition

July 13th 2024

Thermo Fisher will add Olink to its Life Sciences Solutions business.

Pfizer and Evotec Partner for Drug Discovery

Pfizer and Evotec Partner for Drug Discovery

July 12th 2024

Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.

uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen

uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen

July 10th 2024

The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.

Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership

Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership

July 4th 2024

LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.

Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development

Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development

July 2nd 2024

This collaboration aims to support and accelerate clinical development of advanced and novel technologies.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

June 29th 2024

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

June 28th 2024

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases

June 18th 2024

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.